Scholarlink

<p>Cancer driver mutations are defined by their high prevalence in cancers and presumed rarity in normal tissues. However, recent studies show that positive selection in normal epithelia can increase the prevalence of some cancer drivers. To determine their true cancer-driving potential, it is essential to evaluate how frequent these mutations are in normal tissues and what&#xa0;are their phenotypes. Here, we explore the bioavailability of somatic variants by quantifying age-related mutational burdens in normal human colonic epithelium using immunodetection in FFPE samples (<i>N</i> = 181 patients). Positive selection of variants of tumour suppressor genes <i>PTEN</i> and <i>ARID1A</i> associates with monoallelic gene loss as confirmed by CRISPR/Cas9 mutagenesis and changes in their downstream effectors. Comparison of the mutational burden in normal tissue and colorectal cancers allows quantification of cancer driver potency based on relative representation. Additionally, immune exclusion, a cancer hallmark feature, is observed within ARID1A-deficient clones in histologically normal tissue. The behaviour resulting from haploinsufficiency of <i>PTEN</i> and <i>ARID1A</i> demonstrates how somatic mosaicism of tumour suppressors arises and can predispose to cancer initiation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Haploinsufficient phenotypes promote selection of PTEN and ARID1A-deficient clones in human colon

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月7日

查看全文
  • Nefeli Skoufou-Papoutsaki,
  • Sam Adler,
  • Shenay Mehmed,
  • Claire Tume,
  • Cora Olpe,
  • Edward Morrissey,
  • Richard Kemp,
  • Anne-Claire Girard,
  • Elisa B Moutin,
  • Chandra Sekhar Reddy Chilamakuri,
  • Jodi L Miller,
  • Cecilia Lindskog,
  • Fabian Werle,
  • Kate Marks,
  • Francesca Perrone,
  • Matthias Zilbauer,
  • David S Tourigny,
  • Douglas J Winton

摘要

Cancer driver mutations are defined by their high prevalence in cancers and presumed rarity in normal tissues. However, recent studies show that positive selection in normal epithelia can increase the prevalence of some cancer drivers. To determine their true cancer-driving potential, it is essential to evaluate how frequent these mutations are in normal tissues and what are their phenotypes. Here, we explore the bioavailability of somatic variants by quantifying age-related mutational burdens in normal human colonic epithelium using immunodetection in FFPE samples (N = 181 patients). Positive selection of variants of tumour suppressor genes PTEN and ARID1A associates with monoallelic gene loss as confirmed by CRISPR/Cas9 mutagenesis and changes in their downstream effectors. Comparison of the mutational burden in normal tissue and colorectal cancers allows quantification of cancer driver potency based on relative representation. Additionally, immune exclusion, a cancer hallmark feature, is observed within ARID1A-deficient clones in histologically normal tissue. The behaviour resulting from haploinsufficiency of PTEN and ARID1A demonstrates how somatic mosaicism of tumour suppressors arises and can predispose to cancer initiation.